港股概念追踪|创新药企业绩普遍增长上游CXO行业调整基本完成（附概念股）

智通财经2025-11-24

Wind资讯数据显示，在A股CXO板块29家上市公司中，有20家公司实现前三季度营收同比增长。国际化驱动创新药企业业绩增长，位于创新药产业链上游，被称为行业“卖铲人”的CXO板块，也迎来了需求增长，从而推动业绩整体增长。从整体来看，当前创新药产业正迎来政策推动、需求爆发的双重利好，二者正共同激活新药研发需求，并进一步传导至产业链上游的CXO板块。智通财经APP获悉，创新药领域呈现三大趋势：国际化...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2585363594?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-24 08:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585363594","market":"hk","top_or_hot":-1,"title":"港股概念追踪|创新药企业绩普遍增长  上游CXO行业调整基本完成（附概念股）","media":"智通财经","content":"<div>\n<p>Wind资讯数据显示，在A股CXO板块29家上市公司中，有20家公司实现前三季度营收同比增长。国际化驱动创新药企业业绩增长，位于创新药产业链上游，被称为行业“卖铲人”的CXO板块，也迎来了需求增长，从而推动业绩整体增长。从整体来看，当前创新药产业正迎来政策推动、需求爆发的双重利好，二者正共同激活新药研发需求，并进一步传导至产业链上游的CXO板块。智通财经APP获悉，创新药领域呈现三大趋势：国际化...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1372514.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股概念追踪|创新药企业绩普遍增长  上游CXO行业调整基本完成（附概念股）</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股概念追踪|创新药企业绩普遍增长  上游CXO行业调整基本完成（附概念股）\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-24 08:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1372514.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wind资讯数据显示，在A股CXO板块29家上市公司中，有20家公司实现前三季度营收同比增长。国际化驱动创新药企业业绩增长，位于创新药产业链上游，被称为行业“卖铲人”的CXO板块，也迎来了需求增长，从而推动业绩整体增长。从整体来看，当前创新药产业正迎来政策推动、需求爆发的双重利好，二者正共同激活新药研发需求，并进一步传导至产业链上游的CXO板块。智通财经APP获悉，创新药领域呈现三大趋势：国际化...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1372514.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348825331.USD","symbol_name":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1372514.html","article_id":"2585363594","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585363594","pubTimestamp":1763943133,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"国际化驱动创新药企业业绩增长，位于创新药产业链上游，被称为行业“卖铲人”的CXO板块，也迎来了需求增长，从而推动业绩整体增长。从整体来看，当前创新药产业正迎来政策推动、需求爆发的双重利好，二者正共同激活新药研发需求，并进一步传导至产业链上游的CXO板块。CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","06978":"永泰生物-B","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","02359":"药明康德","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1589":"北水核心资产","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","CXO":"康休","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","06821":"凯莱英","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK1141":"生命科学工具和服务","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK1576":"医药外包概念","BK1191":"制药","BK1610":"ETF&股票定投概念","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426480.USD":"法巴中国股票经典Dis","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0823426308.USD":"法巴中国股票基金","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","BK1574":"生物医药B类股","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0051755006.USD":"摩根大通中国A (dist)","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","BK1583":"高瓴概念","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1161":"生物科技","LU0181495838.USD":"施罗德新兴亚洲A Acc","BK1521":"挪威政府全球养老基金持仓","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","02269":"药明生物"},"translate_title":"Hong Kong stock concept tracking | The performance of innovative drug companies has generally grown, and the adjustment of the upstream CXO industry has been basically completed (with concept stocks)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"06821":0.9,"02269":0.9,"06978":1.5,"CXO":1.5,"02359":0.9},"content_text":"Wind资讯数据显示，在A股CXO板块29家上市公司中，有20家公司实现前三季度营收同比增长。国际化驱动创新药企业业绩增长，位于创新药产业链上游，被称为行业“卖铲人”的CXO板块，也迎来了需求增长，从而推动业绩整体增长。从整体来看，当前创新药产业正迎来政策推动、需求爆发的双重利好，二者正共同激活新药研发需求，并进一步传导至产业链上游的CXO板块。智通财经APP获悉，创新药领域呈现三大趋势：国际化2.0纵深发展，2025年license-out交易数达103个、首付款84.5亿美元创历史新高，自主出海企业享受估值溢价；政策支持力度空前，医保谈判效率提升并首次设立商保创新药目录；技术驱动持续突破，ADC、IO双抗、GLP-1减重、小核酸药物多点开花。招银国际认为，资本市场融资活动恢复，创新药出海交易规模扩张，国内创新药研发需求回暖，加上美国进入降息周期，CXO企业下半年业绩表现有望复苏，招银国际预期已授权的创新药管线在海外的临床发展可成为创新药板块最重要催化剂。中信建投证券发布研究报告称，创新药领域呈现三大趋势：国际化2.0纵深发展，2025年license-out交易数达103个、首付款84.5亿美元创历史新高，自主出海企业享受估值溢价；政策支持力度空前，医保谈判效率提升并首次设立商保创新药目录；技术驱动持续突破，ADC、IO双抗、GLP-1减重、小核酸药物多点开花。CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。上游产业链复苏显著，国产化率提升空间广阔，智能化、数字化生产与国际化拓展双轮驱动。看好国内未来制药产业链的发展。CXO板块相关龙头企业：凯莱英(06821)、康龙化成(03759)、昭衍新药(06127)、药明生物(02269)、药明康德(02359)等。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585363594","isCrawlerRequest":true}

港股概念追踪|创新药企业绩普遍增长 上游CXO行业调整基本完成（附概念股）

精彩评论

港股概念追踪|创新药企业绩普遍增长上游CXO行业调整基本完成（附概念股）